Clinical and Planning Approaches for Re-Irradiation-AM2018
Many practices are experiencing increasing numbers of cases for which irradiation of previously treated areas is required. This requires careful consideration of a range of radiobiological, dose discounts for prior treatments, clinical practice flow, documentation and treatment planning issues. This session will cover practical concepts related to treatment planning for re-irradiation in a variety of treatment sites. Many of the concepts are similar so the topics will be discussed together. Speakers will focus on (1) how to determine safe treatment planning goals for re-irradiation cases (2) how to sum dose using prior radiation treatment plans and current plans (3) advanced treatment planning tips for re-irradiation and adaptive therapy. Practical case-based examples will be used in addition to education regarding the basic concepts required.
This activity is available from January 3, 2019, through 11:59 p.m. Eastern time on January 2, 2022.
This activity was originally recorded at ASTRO’s 2018 Annual Meeting, October 22-24, 2018 in San Antonio, TX.
The meeting is designed to meet the interests of radiation oncologists, radiation oncology residents, radiation physicists and radiation dosimetrists.
- Discuss treatment planning considerations for re-irradiation.
- Discuss dose summation techniques and consideration for re-irradiation.
- Explain the limitations and uncertainties associated with planning for re-irradiation.
Mary Feng, MD is employed by the University of California and recieves compensation/remuneration/funding from the University of Michigan, family members recieve compensation/remuneration/funding from ASTRO, Celgene, GenomeDX, Medivation/Astallas, Myriad, Nanostring, Prostate Cancer Foundation, family members hold ownership/investment interests in PFS Genomics, and family members hold leadership positions in NRG.
TJ Fitzgerald, MD is employed by the University of Massachusetts Memorial Medical Center and has no disclosures to declare.
Martha Matuszak, PhD is employed by University of Michigan and recieves compensation/remuneration/funding from Varian Medical Systems.
Additionally, the SA-CME Task Force and the CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.